Abstract
HIV Drug Therapy in the Americas 8–10 May 2014, Rio de Janeiro, Brazil
Highlights
By the end of 2013, Brazil has implemented treatment as prevention (TasP) to every person living with HIV (PLWHA)regardless of their CD4 count, aimed at the reduction of HIV transmission
Whilst VL suppression among those who were on antiretroviral therapy (ART) in the South Region was 77%, in the North Region suppression does not reach 70%
As high as 76% of them were on nucleoside reverse-transcriptase inhibitor (NNRTI) and 24% on protease inhibitor (PI)-based regimens with a median CD4 count of 539 cell/mm We found no differences neither in LAE
Summary
By the end of 2013, Brazil has implemented treatment as prevention (TasP) to every person living with HIV (PLWHA)regardless of their CD4 count, aimed at the reduction of HIV transmission. In this randomized, double-blind controlled Phase 3 trial in treatment-naıve patients, elvitegravir/cobicistat/emtricitabine/tenofovir DF (STB) was non-inferior to efavirenz/emtricitabine/tenofovir. The Medical Outcomes Study Short Form-36 (SF-36) is the most useful questionnaire for assessment of Health Related QoL (functional state), and Beck Depression Inventory (BDI) is the most useful instrument for assessment of depressive symptoms in clinic populations These two instruments were validated in a sample of Mexican people with HIV 1, 2 and 3. The emergence of mutations associated with resistance to antiretroviral drugs (ARV) HIV-1 limits the effectiveness of treatment in HIV-infected patients, leading to virological and immunological failure. The aim of this study was to compare effectiveness of tenofovir/3(F)TC plus NNRTI with zidovudine/lamivudine plus NNRTI first-line regimens at population level, measured as the proportion of persons with suppressed viremia
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
